PGP and atrial fibrillation: Indeed, edoxaban was the only DOAC for which such dose adaptation was validated in its major trial (ENGAGE AF-TIMI 48), unlike the major trials on apixaban and rivaroxaban (ARISTOTLE AF and ROCKET AF trials, respectively), which excluded potent P-gp inhibitors [59,60,61].